SAN

99.3

-3.63%↓

EI

266.2

-0.67%↓

SHL.DE

49.55

-1.14%↓

ARGX

526

-3.56%↓

FRE

38.75

-2.52%↓

SAN

99.3

-3.63%↓

EI

266.2

-0.67%↓

SHL.DE

49.55

-1.14%↓

ARGX

526

-3.56%↓

FRE

38.75

-2.52%↓

SAN

99.3

-3.63%↓

EI

266.2

-0.67%↓

SHL.DE

49.55

-1.14%↓

ARGX

526

-3.56%↓

FRE

38.75

-2.52%↓

SAN

99.3

-3.63%↓

EI

266.2

-0.67%↓

SHL.DE

49.55

-1.14%↓

ARGX

526

-3.56%↓

FRE

38.75

-2.52%↓

SAN

99.3

-3.63%↓

EI

266.2

-0.67%↓

SHL.DE

49.55

-1.14%↓

ARGX

526

-3.56%↓

FRE

38.75

-2.52%↓

Search

Fagron

Atidarymo kaina

SektoriusSveikatos priežiūra

18.92 -0.84

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

18.8

Max

19.14

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-298K

40M

Pardavimai

13M

443M

P/E

Sektoriaus vid.

17.346

63.778

Dividendų pajamingumas

1.58

Pelno marža

9.066

Darbuotojai

3,828

EBITDA

-4.3M

71M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+20.59% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

1.58%

2.39%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

19M

1.4B

Ankstesnė atidarymo kaina

19.76

Ankstesnė uždarymo kaina

18.92

Naujienos nuotaikos

By Acuity

50%

50%

173 / 386 reitingas Healthcare

Fagron Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-04-01 23:15; UTC

Pagrindinės rinkos jėgos

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

2025-04-01 23:46; UTC

Rinkos pokalbiai

Market Grapples With Valuing Goodman's Data Centers -- Market Talk

2025-04-01 23:44; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-04-01 23:44; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-04-01 23:44; UTC

Rinkos pokalbiai

Nikkei May Trade Rangebound Amid U.S. Tariff Uncertainty -- Market Talk

2025-04-01 23:43; UTC

Rinkos pokalbiai

Gold Steady, Underpinned by Signs of Chinese Buying Activity -- Market Talk

2025-04-01 23:11; UTC

Svarbiausios naujienos

Risk Off Trade Is Getting Crowded. It's More Worry Than Panic. -- Barrons.com

2025-04-01 23:02; UTC

Rinkos pokalbiai

New Zealand May Be Measuring Stick for Trade-War Fallout -- Market Talk

2025-04-01 22:31; UTC

Svarbiausios naujienos

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

2025-04-01 22:26; UTC

Rinkos pokalbiai

RBA's Focus on What It Doesn't Know Boosts May Cut Odds -- Market Talk

2025-04-01 21:47; UTC

Svarbiausios naujienos

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

2025-04-01 21:32; UTC

Svarbiausios naujienos

Hooters' Bankruptcy Is the Latest Sign of Trouble for Restaurants -- Barrons.com

2025-04-01 21:06; UTC

Rinkos pokalbiai

Mexican Remittances See Slow Start to the Year -- Market Talk

2025-04-01 21:00; UTC

Rinkos pokalbiai

ESG Roundup: Market Talk

2025-04-01 20:50; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Financial Services Roundup: Market Talk

2025-04-01 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-04-01 20:47; UTC

Svarbiausios naujienos

Boeing Stock Drops. Why Lower 737 MAX Production Report Wasn't Quite Right. -- Barrons.com

2025-04-01 20:47; UTC

Svarbiausios naujienos

BYD Will Beat Tesla Two Ways This Quarter -- Barrons.com

2025-04-01 20:20; UTC

Svarbiausios naujienos

Trump's 'Liberation Day' Tariffs Loom; Treasury Yields Fall -- WSJ

2025-04-01 20:15; UTC

Įsigijimai, susijungimai, perėmimai

Eaton Completes Acquisition Of Fibrebond >ETN

2025-04-01 20:11; UTC

Rinkos pokalbiai

Altria Stock Seen Overvalued Amid Steep Volume Losses -- Market Talk

2025-04-01 20:07; UTC

Įsigijimai, susijungimai, perėmimai

Johnson & Johnson Intends to Complete Its Acquisition of Intra-Cellular Therapies on or Around April 2 >JNJ

2025-04-01 20:00; UTC

Svarbiausios naujienos

Americans Are Worried About Tariffs. Consumer Stocks Could Take a Hit. -- Barrons.com

2025-04-01 19:46; UTC

Svarbiausios naujienos

Visa, American Express Bidding to Win Apple Credit-Card Network, Sources Say -- WSJ

2025-04-01 19:43; UTC

Rinkos pokalbiai

Oil Rally Loses Momentum Ahead of U.S. Tariff Plans -- Market Talk

2025-04-01 19:17; UTC

Svarbiausios naujienos

Meta's Head of AI Research to Resign Amid Computing Push -- Update

2025-04-01 19:13; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Give Back Gains -- Market Talk

2025-04-01 19:03; UTC

Rinkos pokalbiai

Don't Rush Into Trade Talks With U.S., Canadian Experts Advise Lawmakers -- Market Talk

2025-04-01 19:00; UTC

Rinkos pokalbiai

Gold Slips Ahead of Tariff Day -- Market Talk

2025-04-01 18:54; UTC

Rinkos pokalbiai

Mexican Manufacturing PMIs Reflect Tariff Threats -- Market Talk

Akcijų palyginimas

Kainos pokytis

Fagron Prognozė

Kainos tikslas

By TipRanks

20.59% į viršų

12 mėnesių prognozė

Vidutinis 19.5 EUR  20.59%

Aukščiausias 19.5 EUR

Žemiausias 19.5 EUR

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Fagron kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

1

Pirkti

0

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

173 / 386 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Fagron

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; and SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort. In addition, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.